In:
CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, New Century Health Publishers LLC, Vol. 21, No. 4 ( 2023-10-09), p. 386-394
Abstract:
We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P 〈 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P 〉 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.
Type of Medium:
Online Resource
ISSN:
1540-7535
,
2641-452X
DOI:
10.37290/ctnr2641-452X.21:386-394
Language:
Unknown
Publisher:
New Century Health Publishers LLC
Publication Date:
2023
detail.hit.zdb_id:
2455097-8
Permalink